William F. Regine, MD, FACR, FASTRO, FACRO

Executive Director, Maryland Proton Treatment Center; Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology, Interim President, University of Maryland Faculty Physicians, Inc.,

Named a Top Radiation Oncologist by Baltimore Magazine

Dr. Regine is a leader in the field of radiation oncology and a recognized expert in the areas of GI and CNS malignancies. He has served as a principal investigator for multiple NCI-sponsored clinical trials. His research has defined new standards of care for patients. He is co-inventor of the “GammaPod,” the first treatment system dedicated to the stereotactic radiation of early stage breast cancer and is co-editor of “Principles and Practices of Stereotactic Radiosurgery,” the first comprehensive textbook of its kind.

Special Interests: Base of skull/paranasal sinuses, Central nervous system (brain/spine), Esophagus, GI (anus/rectum/stomach/colon/liver/pancreas), Head and neck (non-paranasal sinuses), sarcoma

Medical Degree: State University of New York Health and Science Center

Residency: Thomas Jefferson University Hospital

Physician Fellowships: Thomas Jefferson University Hospital and University of Florida, Radiation Oncology

Certification: Radiation Oncology

To learn more about Dr. Regine, please watch the video below:

Education and Training

• State University of New York at Albany, BS, 1983
• State University of New York Health and Science Center at Syracuse, MD, 1987
• Residency, Thomas Jefferson University Hospital, Radiation Oncology, 1991
• Fellowship, Thomas Jefferson University and University of Florida Hospitals, Radiation Oncology-Head and Neck and Gastrointestinal Malignancies, 1992

Biosketch

Dr. Regine leads a department which has achieved a Top 5 national ranking in National Institutes of Health research funding. He is recognized nationally and internationally in the areas of gastrointestinal and central nervous system malignancies and in the use of stereotactic radiosurgery (SRS). As Executive Director of the Maryland Proton Treatment Center, he leads the first and most advanced facility of its kind in the Batlimore-Washington, DC region — providing nearly 2,000 cancer patients a year with precise, “pencil-beam” technology to treat solid tumors.

In this video, Dr. Regine talks about proton therapy and the Maryland Proton Treatment Center:

Dr. Regine has served as principal or co-principal Investigator in at least four National Cancer Institute (NCI)-sponsored cooperative group clinical trials. He is a member of the GI and Brain Tumor steering committees for the NCI sponsored national cooperative clinical trials group known as NRG Oncology, and is the recent chairman of the GI section of the National Oral Board examination for trainees in radiation oncology. Dr. Regine served as the principal investigator of a study evaluating adjuvant therapy in patients with pancreatic cancer, which defined a new standard of care. He also has been the principal investigator/study chairman for two institutional clinical trials that defined new standards of care for patients with brain metastases and malignant spinal cord compression. Dr. Regine is co-editor of Principles and Practices of Stereotactic Radiosurgery, the first comprehensive textbook of its kind. He is also co-inventor of the first of its kind treatment device completely dedicated to the stereotactic radiation treatment of early stage breast cancer, known as the GammaPod.

Research/Clinical Keywords

Pancreas/Gastrointestinal Cancers, Central Nervous System Malignancies, Brain Metastases/Tumors, Head and Neck Cancers, Sarcomas, Stereotactic Radiosurgery (SRS), Proton Treatment

Highlighted Publications

Lin J, Lin M, Hall A, Singh D, Regine WF. Comparison of Bolus Electron Conformal Therapy plans to Traditional Electron and Proton Therapy to Treat Melanoma in the Medial Canthus. Practical Radiation Oncology (2016) Issue 6, Pages: 105-109, March 2016. Chang L, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman G, Guha C, Abbruzzese JL, Li Donghui. RECQ1 A159C Polymorphism is Associated with Overall Survival of Patients with Resected Pancreatic Cancer: A Replication Study in RTOG 9704. Int. J. Radiation Oncology Biol.Phys., 94:(3), Pages 554-560, March 2016. Chin LS, Regine WF. Editors. Principles and Practice of Stereotactic Radiosurgery, Second Edition, Springer Publishing, 2015. Mattiucci G.C., Falconi M., Stiphout R., Alfieri S., Calvo F., Maidment III B., Miller R., Regine WF, Reni M., Sharma N., Genovesi D., Balducci M., Deodato F., Valentini V., Morganti A. Adjuvant Chemoradiation in pancreatic cancer: a pooled analysis in elderly (≥ 75 years) patients. Scopus, Anticancer Research, 35(6):, 3441-3446, June, 2015. Chuong M, Mehta, MP, Langen K, Regine WF. Is Proton Beam Therapy Better Than Standard Radiation Therapy? Clinical Advances in Hematology & Oncology, Volume 12, Issue 12, Pages: 861-869, December 2014.